1.Determination of Lysophosphatidic Acid by an Enzymatic Cycling Method
Journal of Chinese Physician 2001;0(09):-
Objective To establish a method of testing lysophosphatidic acid (LPA) by enzymatic cycling. Methods The detection system was developed on the principle of enzymatic cycling method and characteristic of LPA. The methodology was evaluated and the content of LPA was tested in 20 samples of plasma with ovarian carcinoma. Results The linearity was 18.6?mol/L and the detection limit was 0.03?mol/L. The within-run and between-run coefficient of variations were 5.3% and 7.4%, respectively. The recovery was 100.7% and there was a significant correlation with the liquid chromatography method(Y=0.953X+0.51). The reagent system was stable and different concentrations of bilirubin, hemoglobin, triglyceride, glucose, urea and ascorbate did not affect the measurement for the assay. The content of LPA in 20 samples of plasma with ovarian carcinoma was significantly higher than that in control group (P
2.Nonmyeloablative stem cell transplantation followed by donor stem cell infusion for the treatment of nonmalignant haematologic diseases
Qingshan LI ; Ping MAO ; Jiade DENG
Journal of Chinese Physician 2000;0(11):-
Objective To evaluate the efficacy and complications of nonmyeloablative stem cell transplantation(NST) for the treatment of nonmalignant haematologic diseases with high-risk rejection.Methods NST was performed for two patients with severe aplastic anemia(SAA) and one with beta-thalassemia major(TM).The protocal was designed on transplantation of granulocyte colony-stimulating factor(G-CSF) primed allogeneic bone marrow cells combined with perpheral blood stem cells(PBSCs) for two SAA patients,with conditioning regimen based on anti-lymphocyte globulin and reduced dose of cyclophosphamide(CTX).One TM patient was performed transplantation of PBSCs with conditioning regimen of anti-T-lymphocyte globulin(ATG),fludarabine and reduced dose of busulfan.Cyclosporin A combined with methylprednisone was used for graft-versus-host disease(GVHD) prophylaxis.Donor stem cells infusion(DSI) were underwent for three patients at 78,99 and 44 days post transplant respectively.Results Three patients achieved engraftment successfully with mixed chimera and the lowest white blood cell(WBC) of 0.26?10~9/L,0.5?10~9/L and 1.26?10~9/L respectively.The absolute neutrophil count achieved more than 0.5?10~9/L and platelet count achieved more than 20?10~9/L at days of 12d,3d,0d and 1d,5d,0d post transplant in three patients,respectively.The haematopoiesis and chimera were improved after DSI without complications of infection and GVHD in three patients.Conclusion The stem cells engraftment is achieved successfully with donor stem cell infusion followed NST for the treatment of nonmalignant haematologic disease patients with high-risk rejection.
3.Morphological characteristics of damaged Hero642 Ni-Ti dental files
Yuan LI ; Yue LIN ; Wang JIADE
Journal of Practical Stomatology 2000;0(05):-
Objective:To analyze the morphological characteristics of damaged Hero642 Ni-Ti dental files, and explain the relationship between deformation and fracture.Methods:71 discarded files were observed under naked eyes and stereomicroscope. 5 of which were observed under S360 scanning electronic microscope (SEM), and typical photos were taken for analysis.Results:The damage of Hero642 Ni-Ti dental files was characterized by fracture, tightened or loosened spiral and some kind of deformation detected at more than 35 times magnification. Under SEM, the dimple pattern was represented in the fracture surface of the files. Conclusion:Most Hero642 Ni-Ti files fractured within 4 mm from the tip which belongs to the pattern of ductile fracture.
4.Targeted therapy of metastatic renal cell carcinoma
China Oncology 1998;0(01):-
Surgery is the only curative treatment modality for renal cell carcinoma (RCC). However, approximately 30% of patients who undergo successful nephrectomy for RCC will develop locoregional or metastatic recurrence. Effective treatment for recurrent or metastatic RCC is limited. It is known that conventional radiation therapy and chemotherapy are relatively ineffective for RCC patients with distant metastases. Although immune therapy with high dose interleukin can provide disease control for a portion of patients with advanced RCC, its therapeutic effect usually is not sustainable. In addition, substantial adverse effects and complications have limited the use of high dose interleukin treatment. Advances in the understanding at the molecular level of cancer have led to much progress in the development of anti-cancer agents, including drugs of targeted cancer therapy. Targeted therapy is not only effective in cancer treatment, but also has reduced adverse effects compared with conventional chemotherapy and immune therapy. Much progress in the treatment of advanced RCC by targeted therapy has been achieved in recent years. In this review, we will illustrate the roles, mechanisms and effects of several targeted therapy agents, including the two newly FDA-approved drugs, sorafenib and sunitinib, in the treatment of advanced renal cell carcinoma.
5.The effect of malignant ascites on the proliferation and migration of ovarian cancer cells
Shuang GUO ; Duanyang LIU ; Jing LI ; Jiade LI ; Xiaoming JIN
Practical Oncology Journal 2016;30(1):36-40
Objective To evaluate the effects of malignant ascites on the morphological characteristics and the proliferation and migration abilities of the tumor cell and ovarian cancer cell lines(SKOV3)in the ovarian cancerous ascites.Methods Tumor cells extracted from the ovarian cancerous ascites were cultured in vitro with DMEM high glucose culture medium,and ovarian cancer cell lines( SKOV3) were cultured in DMEM high glucose and DMEM high glucose with different proportion of malignant ascites.The morphological characteristics of the cells were observed by optical microscope and electron microscope respectively.Cell proliferation ability was de-tected by CCK kit;The effect of SKOV3 on the migration of ovarian cancer cell lines was measured by scratch test.Results The morphological characteristics of tumor cells and ovarian cancer cell lines( SKOV3) in ovarian cancer ascites were significantly different.The proliferation ability of tumor cells was decreased without the asci-tes.The proliferation and migration abilities of SKOV3 cultured in mixed culture medium were significantly im-proved compared with the cells cultured in high glucose medium.Conclusion The change of tumor cell morphol-ogy in ascites benefits its abilities of proliferation and migration.The malignant ascites promote the abilities of pro-liferation and migration of ovarian cancer cell line(SKOV3).
6.Cyr61 expression influences cancer cell proliferation and apoptosis via PI3K pathway in human ovarian carcinoma cells
Lan XIAO ; Chan HE ; Xin LI ; Ying CHEN ; Jiade ZHOU
Chinese Journal of Obstetrics and Gynecology 2012;47(8):616-620
Objective To investigate the relationship between cysteine-rich protein 61 ( Cyr61 ) and phosphatidylinositol 3-kinase ( PI3K ) signal pathway on cell proliferation and apoptotic in human ovarian carcinoma cells.Methods Recombinant human Cyr61 (rhCyr61) was pretreated with ovarian carcinoma cells.The expression of Cyr61 protein was detected by confocal spectral microscopy.Then treated the ovarian carcinoma cells with PI3K transduction inhibitors (LY294002) for 24 hours.Cell apoptosis was detected by flow cytometry (FCM).Cell viability was determined by methyl thiazolyl tetrazolium (MTT) method.The mRNA expressions of Cyr61,the protein levels of protein kinase B ( PKB),phospho-PKB and Cyr61 were assaved by real time-PCR and western blot analysis,respectively.Results The Cyr61 and phospho-PKB protein expression in two ovarian carcinoma cells (OV2008 and OVCAR-3 ) were increased in rhCyr61pretreated group.The decreasing of cell apoptosis [ ( 1.4 ±0.9)%,(2.1 ± 1.0)% ] and increasing of cell proliferation [ ( 124.0 ± 1.8)%,( 133.0 ±2.2)% ] was detected in the same time,compared with negative control group,there were significant difference ( P < 0.05 ).After exposed to LY294002 for 24 hours,the apoptosis rate of OV2008 and OVCAR-3 in pretreated with rhCyr61 group exposed to LY294002 were (21.1 ± 1.6)% and (26.4 ± 1.5 )%,respectively.Cells viability [ (59.0 ± 2.3 )%,(51.0 ± 2.0)% ]was also significantly decreased in OV2008 and OVCAR-3 pretreated with rhCyr61 cells.Meanwhile,the mRNA expressions of Cyr61 (3.2 ± 0.8,6.2 ± 1.1 ) and the protein levels of phospho-PKB and Cyr61 were greatly decreased.Compared with negative control group,there were significant difference in OV2008 and OVCAR-3 cells (all P < 0.0l ).Conclusions The activation of PI3K intracellular signaling pathways may lead to up-regulation of Cyr61 expression.Block PI3K signal pathway could significantly inhibit the expression of Cyr61,and may promote the apoptotic effects and inhibit the cell growth of ovarian carcinoma cells.
7.Controversies and consensus of the adjuvant therapy of pancreatic cancer
Jun ZHANG ; Jiade LU ; Chenghong PENG ; Hongwei LI
China Oncology 2009;19(8):580-584
Pancreatic cancer is a highly malignant neoplasm with dismal prognosis. The risk of recurrence and metastasis remains high even for patients who have undergone radical dissection. Therefore, adjuvant therapy after "curative" resection is crucial. However, consensus on the optimal management of pancreatic cancer after surgery has not been reached. Both chemotherapy and concurrent chemoradiation therapy have been advocated. Yet, based upon the results of published phase Ⅲ trials, the consensus and standard strategy of adjuvant treatment after pancreatic cancer surgery is still undo" debate. According to the results of GITSG and RTOG trials, the mainstream in North American is adjuvant chemoradiation. However, based on the results of ESPAC-1 and CONKO-001 studies, the oncologists in Europe usually recommend chemotherapy alone. Furthermore, the superiority of gemcitabine over 5-FU in the adjuvant setting is largely unclear. This article reviewed the main results of the clinical trials in the field of adjuvant treatment of pancreatic cancer.From the authors' view, both the standard dosage of gemcitabine (CONCO-001) and chemoradiation (RTOG-9704) after resection of pancreatic cancer could be considered as candidates for adjuvant strategy. However, the optimal therapy will have to be determined by trials with larger number of patients.
8.Study on the reliability of tooth wear index among middle-aged and elderly people
Yi JIANG ; Qing ZHANG ; Jiade WANG ; Ping LI
Chinese Journal of Geriatrics 2003;0(07):-
Objective To determine the reliability of the tooth wear index in representing the profile of tooth cervical defect. Methods One hundred and ninety-three teeth with wedge-shaped defects were selected in 69 plaster casts. The sizes of every wedge-shaped defect were measured by using vernire caliper and the volumes of those were calculated. Otherwise, by weighting the restoration of defects, the real volumes of the 9 teeth defects were calculated by formulating. Results The formulation for calculatin of the real volume of the defects was presented as: volume = 0.4735 + 2.5948 X (deep of profile X height X broad of defects)/6. The profile of the defect was strongly related to the volume. Conclusions The value of one dimension measure of the wedge-shaped defects may present the tooth wear index.
9.Brief introduction of revised receipt printing program for military healthy information management system
Lun WANG ; Jiade LI ; Hongshan MAO ; Min GUO ; Shuli LI ; Yu GE
Chinese Medical Equipment Journal 2003;0(12):-
The military healthy information management system follows No.1,No.2 and No.3 military medical projects.This paper introduces the methods of revising receipt printing program in seven parts.
10.Impact of rhG-CSF mobilization on TH17/Treg cells in donors' peripheral blood
Qingshan LI ; Zao CHEN ; Qinghua DU ; Jiade DENG ; Yanying LING ; Xuejie JIANG ; Fanyi MENG
Chinese Journal of Organ Transplantation 2013;34(11):680-684
Objective To explore the effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) mobilization on TH17/Treg cells and its impact on suppressor of cytokine signaling-3 (SOCS3) gene expression in CD4+ T cells in donors' peripheral blood.Method Sixteen donors were injected subcutaneously with rhG-CSF 5 μg/kg every day for 5 consecutive days for peripheral blood stem cells mobilization.At the first 0,3,5 day,the mononuclear cclls (MNCs) in peripheral blood or graft and serum specimens were taken.The CD4 + T cells in MNCs were sorted using immuno-magnetic beads.The ratio of TH 17 and Treg cells in MNCs,cytokines concentrations of IL-17A,IL-21,ID23 and TGFβ1 in serum,and SODC3 gene expression in CD4+ T cells were detected by using flow cytometry,ELISA,and reverse transcription real-time quantitative PCR (RT-qPCR),respectively.Results (1)The ratio of Th17 cells (CD3+ CD8 CD17+) and Treg cells (CD4+ CD25+ Foxp3+) in MNCs in peripheral blood and graft at the first 0,3 and 5 days after mobilization was (2.69 ± 0.81) %,(0.91 ± 0.33) %,(0.35 ± 0.12) %,(0.21 ± 0.05) %,and (0.56 ± 0.24) %,(0.72 ± 0.22%),(1.59 ± 0.54) %,(3.38 ± 0.52) %,respectively,showing a significant declining and increasing trend respectively (P<0.05); (2)The cytokine concentrations in serum at the first 0,3 and 5 days after mobilization were 7.33 ± 0.89,5.78 ± 1.03 and 3.32 ± 0.84 μg/L for IL-17A; 124.56 ± 15.18,117.12 ± 14.45 and 64.94 ± 11.25 μg/L for IL-21 ; 183.52 ± 59.35,280.49 ± 69.75 and 393.62 ± 57.25μg/L for TGF-β1 (P<0.01) ; and 45.89 ± 6.95,46.25 ± 7.44 and 47.45 ± 10.75 μg/L for IL-23,respectively.The IL-17A and IL-21 concentrations showed significant declining trend,contrarily TGF-β1 with an increasing trend,while IL-23 concentration had no change.After rhG-CSF mobilization,the SOCS3 gene expression in CD4 + T cells of peripheral blood and graft at the first 0,3,5 days was gradually increased.Conclusion rhG-CSF suppresses Th17 cells and promotes regulatory T cells generation,meanwhile decreases IL-17A and IL-21 and elevates serum TGF-β1 concentrations,and contributes to CD4 + T cells differentiation to Tregs,probably by elevating SOSC3 gene expression in CD4+ T cells.